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Statins in combination with fibrates show beneficial effects on the lipoprotein profile of
patients because they have positive complimentary effects on lipid profile. A new green
ultrahigh-performance liquid chromatographyediode array detector method for simulta-
neous analysis of simvastatin (SMV) and fenofibrate (FNF) in standard form, marketed
formulations, and self-emulsifying drug delivery system formulations was developed and
validated in the present investigation. The method utilized C18 as stationary phase and a
combination of methanol:water (8:2) as an eluent. It was found that selected eluent pro-
vided short run time (2.5 minutes), better peak symmetry and satisfactory values of other
chromatographic parameters such as resolution (Rs¼ 2.325), capacity factor (k, 3.0 and 4.2
for SMV and FNF, respectively), selectivity (a ¼1.4), and number of theoretical plates (N,
4265 and 5285 for SMV and FNF, respectively). An excellent linear relationship (r2 0.998 and
0.997 for SMV and FNF, respectively) was observed for linear regression data for the cali-
bration plots. The developed system was validated for accuracy, precision, robustness (˃ 2%
for both drugs) and recovery (98e102% for both drugs). Results obtained from the statistical
treatment of the values obtained for different parameters proved that the method is
suitable, reproducible, and selective for the simultaneous analysis of SMV and FNF in bulk,
marketed, and self-emulsifying drug delivery system formulations. The replacement of
commonly applied toxic solvents with innocuous and environmentally benign solvents
provides a better option than the more toxic processes in drug analysis.
Copyright © 2016, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).e in Biotechnology Resear
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j o u r n a l o f f o o d and d r u g an a l y s i s x x x ( 2 0 1 6 ) 1e821. IntroductionHyperlipidemia, characterized by the presence of an increased
lipid concentration in the blood is one of the indicative factor
(combined with other factors such as hyperglycemia, obesity,
high blood pressure, and defective fibrinolysis) for cardiovas-
cular disease. It is also a potential factor for the development
of atherosclerosis in diabetes mellitus [1e3]. Co-
administration of statins and fibrates have been suggested
by The National Cholesterol Education Program Adult Treat-
ment Panel III for the management of patients with
hyperlipidemia
Statins in combinationwith fibrates show beneficial effects
on the lipoprotein profile of patients with combined hyper-
lipidemia, and this is well accepted with a safety profile the
same as individual monotherapies [4,5]. Chemically, statins
are 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors
that possess the property of inhibiting the production rate of
cholesterol in the body [6]. Fibrates have been found to
decrease the production and elevate the rate of breakdown of
cholesterol and triglycerides in the body by promoting b-
oxidation of fatty acids primarily in the peroxisomes and
partly in mitochondria [7,8]. Both statins and fibrates have
been found to work through different pathways and have
positive complimentary effects on the lipid profile of patients
[9]. Due to their inherent property of exhibiting poor water
solubility and low absorption after oral administration, both
simvastatin (SMV) and fenofibrate (FNF) are considered to be
Class II drugs in the Biopharmaceutical Classification System.
Limited solubility in physiological fluids combined with low
permeability through the gastrointestinal membrane limits
in vivo absorption and thus bioavailability of such drugs,
which is a hindrance in the development of suitable dosage
forms [10]. Many different formulation strategies have been
proposed and practiced for improving the solubility and
bioavailability of hydrophobic compounds such as complex-
ation with b-cyclodextrin or caffeine, salt formation, conju-
gation to dendrimers and use of cosolvents have been
employed to solubilize hydrophobic compounds.
Lipid-based drug delivery systems are one of the most
popular approaches in the field of drug delivery with range
from simple solutions or suspensions of drugs in lipids to
complex mixtures of oils, surfactants, cosurfactants and
cosolvents. Many of these mixtures are characterized as self-
emulsifying drug delivery systems (SEDDS) [11,12]. In order to
overcome the challenge of increasing bioavailability of hy-
drophobic drugs, SEDDS is a promising technique that keeps
the drugmolecule in solubilized form in the tiny droplets of oil
(in amixture of surfactant and oil), as a result of which greater
interfacial surface area becomes available for enhanced ab-
sorption of drug molecule. This mixture has the ability of
forming oil-in-water emulsions when its gets shaken by
gastrointestinal movements [13]. In addition, lipid as a con-
stituent of the formulation also plays its part in improving
bioavailability by increasing drug absorption.
Many analytical techniques are used for the determination
of statins or FNF in standard form, developed formulations,
and plasma as well as in in-vivo and in-vitro studies [14,15].
However, a literature survey of recent years revealed that fewPlease cite this article in press as: Alghazi M, et al., Simultaneous s
mance liquid chromatographyediode array detector method: Improvi
Analysis (2016), http://dx.doi.org/10.1016/j.jfda.2016.03.008studies were performed for the simultaneous determination
of statin and fibrates irrespective of the fact that it is prefer-
able to prescribe coadministration of statins with fibrates for
patients with dyslipidemia [16].
Ultrahigh-performance liquid chromatography (UHPLC) is
a relatively new and advanced liquid chromatographic tech-
nique that makes the resolution possible in significantly less
time because of very fine particle size columns (approx. 3 mm)
with significantly lower consumption of eluents [17]. Ator-
vastatin and its pharmaceutical formulation with FNF is not
official in any pharmacopoeia yet. As a result, there are very
few reports on the simultaneous analysis of SMV and FNF in
the literature. This study was undertaken with the aim of
developing a UHPLCediode array detector (DAD) method for
the concurrent analysis of SMV and FNF in standard form and
marketed formulations. Derivative ratio spectrophotometry
and chemometric calibrations method has been described for
simultaneous separation of atorvastatin and FNF [18e20].
In spite of their environmentally adverse effects, the most
commonly used solvents as mobile phase in HPLC are volatile
organic solvents such as acetonitrile. These solvents require
special treatment before being discharged into the water
bodies or land. Among the principles of green chemistry, there
is great emphasis for promoting the use of alternative solvents
and auxiliaries to decrease the adverse environmental impact
of toxic solvents [21]. Literature review over 15 years clearly
indicates the elevated use of environmentally safer solvents
[22e25]. Capello et al [26,27] proposed a concept for the envi-
ronmental impact of solvents that is based on the application
of two environmental evaluation methods with varying
scopes. The first is the environmental, health, and safety
assessment method [28] that evaluates the potential hazards
of chemicals. The other method, the life-cycle assessment
method, was employed for a complete assessment of releases
to the environment as well as resource use over the full life-
cycle of a solvent. Based on this study, to our surprise, it was
found that methanolewater mixture was environmentally
favorable in all proportions and this acceptability increases
with increasing water content. Therefore, the mixture of
methanol and water was put to test for the analysis of SMV
and FNF (Figure 1) in bulk drug, marketed products, and
laboratory-prepared SEDDS formulation by UHPLC-DAD
technique. The developed method was capable to resolve
these compounds with a run time under 2 minutes. The effect
of constituents of SEDDS in the analysis of SMV and FNF was
also performed to check the possible interference.2. Materials and methods
2.1. Chemicals and reagents
SMV (purity 99.9%) was purchased from Riyadh Pharma
(Riyadh, Saudi Arabia). FNF (purity 99.99%) was purchased
from SigmaeAldrich (St Louis, MO, USA). HPLC grade meth-
anol was procured from BDH Laboratory supplies (Liverpool,
UK). All other reagents and chemicals employed were of
analytical reagent quality. Commercial tabletsdlipanthyl
200M (Solvay Pharmaceuticals, Marietta, GA, USA) for FNF and
Zocor 10 mg for SMV (Merck, Sharp & Dohme, Kenilworth, NJ,eparation of antihyperlipidemic drugs by green ultrahigh-perfor-
ng the health of liquid chromatography, Journal of Food and Drug
Figure 1 e Structures of (A) simvastatin and (B) fenofibrate.
j o u rn a l o f f o o d and d r u g a n a l y s i s x x x ( 2 0 1 6 ) 1e8 3USA)dwere obtained from the local market of Riyadh, Saudi
Arabia. SMV and FNF SEDDSwas prepared in the laboratory by
the spontaneous emulsification method using Imwitor 308
(I308, 98% monocaprylate) as the oil phase, cremophor EL as
surfactant, transcutol as cosurfactant and distilled water as
an aqueous phase.
2.2. Instrumentation and chromatographic conditions
Simultaneous analysis of SMV and FNF was done at room
temperature (22± 1C), with Thermo Scientific UHPLC system
(Thermo Scientific, Karlsruhe, Germany) provided with a 3000
LC pump, 3000 autosampler, binary pumps, a programmable
DAD detector, ultimate 3000 column oven, ultimate 3000
controller, and an inline vacuum degasser, and based on
Chromeleon software, version 6.8. Chromatography was per-
formed on a Thermo Hypersil GOLD 50 2.1 mm reversed
phase C18 column (Thermo Scientific) having a 1.9-mm size
particle as static phase. The mobile phase consisted of
methanolewater (80:20, v/v). The chromatography was done
at a flow rate of 0.4 mL/min with DAD detection at 240 nm.
Samples (1 mL) were introduced using an ultimate 3000 series
Thermo auto sampler.
2.3. Preparation of SMV and FNF stock solution
Linearity plot for SMV and FNF was plotted in concentration
range of 0.05e100 mg/mL. Working dilutions in the desired
range were prepared from the stock solution (100 mg/mL) by
suitablymixing the required aliquots with themobile phase to
get the desired concentration.
2.4. Method development
Various mixed organic/hydro-organic solvent systems as
mobile phase were tried for the development of suitable
UHPLCeDAD method for the simultaneous quantification of
SMV and FNF in its standard drug compound. Various pa-
rameters were kept in mind while deciding the suitability of
any solvent or mixture of solvents to be used as mobile phase
such as appropriateness for stability studies, sensitivity of the
developed method, time consumed for the analysis, peak
parameters, mutual miscibility of the constituent solvents,Please cite this article in press as: Alghazi M, et al., Simultaneous s
mance liquid chromatographyediode array detector method: Improvi
Analysis (2016), http://dx.doi.org/10.1016/j.jfda.2016.03.008and the economy of the solvents. Based on the above criteria,
various mobile phases such as methanolewater, meth-
anolephosphate buffer, acetonitrileephosphate buffer,
methanolesodium percholate buffer, and acetonitrileeso-
dium percholate buffer in varying proportions were tried.
Among the various tried solvents systems for UHPLC quanti-
fication, a combination of methanolewater (80:20, v/v) was
selected as most suitable eluent for subsequent studies.
2.5. Validation studies
The newly developed UHPLCeDAD method was validated for
various parameters such as linearity, precision, accuracy,
robustness, sensitivity and specificity [29,30]. Freshly made
dilutions in the concentration range of 0.05e100 mg/mL were
used for plotting of linearity curves. The solvent system con-
sisting of methanolewater (80:20, v/v) was dispatched at
0.4 mL/min for bringing the column to equilibrium and the
baseline was continuously observed and monitored during
the entire process. The drugs SMV and FNF were detected at
240 nm. The freshly prepared dilute solutionswere introduced
into the system in the multiples of three and peak areas were
recorded using the UHPLC system for each solution and cali-
bration was obtained by plotting concentration vs. peak area.
Accuracy of the developed method was assessed by pre-
viously reported standard addition method. The standard
target SMV and FNF solution (10 mg/mL) was mixed with 0%,
50%, 100%, and 150% surplus drug standard solution and
reanalyzed by the newly developed UHPLCeDAD method.
Each experiment was done in triplicate. Percent recovery,
standard deviation (SD), and standard error for each concen-
tration were calculated.
Precision of the newly developedUHPLCeDADmethodwas
estimated at two different levels, i.e. repeatability (intraday
precision) and interday (intermediate) precision. Intraday
precision of the proposed UHPLCeDAD method was carried
out by quantification of five different concentrations of SMV
and FNF (5 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/
mL) three times on the same day. However, intermediate
precision of the proposed UHPLCeDAD method was deter-
mined by reanalyzing the samples on three different days.
The robustness of the proposed UHPLCeDAD method was
determined to evaluate the effect of deliberate changes made
in the chromatographic conditions on the analysis of SMV and
FNF. The concentration (10 mg/mL) of SMV and FNF was
selected for this purpose. Robustness of the proposed
UHPLCeDAD method was evaluated by slightly increasing as
well as decreasing themobile phase flow rate from 0.4mL/min
to 0.5 mL/min and 0.3 mL/min, wavelength of detection from
240 nm to 250 nm and 270 nm, and by varying the ratio of
methanol:water in mobile phase from 80% to 90% and 70%.
2.6. Marketed product analysis
Commercially available tablets were crushed to fine powder.
An accurately weighed portion of the powder equivalent to
5 mg, 25 mg, and 50 mg of both SMV and FNF was taken
together in 50 mL volumetric flask. Methanol (about 30 mL)
was added to the flask followed by sonication in an ultrasonic
bath for 3 minutes. After sonication, about 20 mL methanoleparation of antihyperlipidemic drugs by green ultrahigh-perfor-
ng the health of liquid chromatography, Journal of Food and Drug
j o u r n a l o f f o o d and d r u g an a l y s i s x x x ( 2 0 1 6 ) 1e84was further added to make up 50 mL and sonicated for 5 mi-
nutes. The solutionwas then filtered using 0.45 mmnylon filter
and, after discarding the first few mL, filtrate was collected.
Five mL of this filtrate was transferred to 50 mL volumetric
flask, diluted to volume with diluent and stirred suitably for
proper mixing.
2.7. Application of UHPLCeDAD method for the
simultaneous assay SMV and FNF in SEDDS
The validity of UHPLCeDAD method was identified by
applying it for the assay of SMV and FNF in SEDDS. SEDDS
formulation of SMV and FNFwas prepared in the laboratory by
spontaneous emulsification method using Imwitor 308 (I308,
98% monocaprylate) as the oil phase, cremophor EL as sur-
factant, Transcutol as cosurfactant, and demineralized water
as the aqueous phase. To analyze the amount of SMV and FNF
in prepared SEDDS (having 5 mg/mL each of SMV and FNF:
single dose), 1 mL of SEDDS was properly diluted with eluent
to make 100 mL of stock solution, which was subsequently
sonicated for 10minutes and then evaluated for the amount of
SMV and FNF present in SEDDS. [27]. The prepared stock so-
lution was then sonicated for about 1 hour and subjected to
UHPLCeDAD analysis for determination of SMV and FNF
content in the formulation. The interactions between SMV
and FNF and nanoemulsion components were also investi-
gated by the proposed method.3. Results and discussion
3.1. Chromatography and method validation
The important criteria for development of successful UHPLC
method for analysis of SMV and FNF in bulk drug and in
marketed formulations were: the method is expected to beFigure 2 e Representative chromatogram showing separation o
were: SMV 1.613 minutes and FNF 2.093 minutes. Column: The
column having a 1.9 mm size particle. Mobile phase: methanole
detection at 240 nm. Analysis of SMV and FNF was done at room
was 10 mg/mL.
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mance liquid chromatographyediode array detector method: Improvi
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well as be accurate, reproducible and robust. It should also be
able to analyze drugs in the presence of SEDDS components
and simple enough for routine use in quality control
laboratory.
During themethod development step, use ofmethanol and
phosphate buffer (component of phosphate buffer (pH 7) was
monobasic potassium phosphate and sodium hydroxide) as
the mobile phase produced asymmetric peak with a larger
tailing factor (> 2) and fewer number of theoretical plates (<
2000). Further, acetonitrile was tried in combination of phos-
phate buffer at different proportions at flow rate of 0.5 mL/
min. The chromatogram was obtained with unsatisfactory
peak parameters. In yet another attempt to get a satisfactory
peak having asymmetry factor ˂ 2 and good sensitivity,
methanol and water were tried as another eluting phase.
Various compositions ofmethanol andwater were tested, and
the binary proportion at 80%:20% v/v was found superior with
a sharp peak, appropriate retention time and fine asymmetry.
Thus,methanol andwater at 80:20was used to develop a facile
and quickmethod for SMVand FNFwith a reasonable run time
(2.50 minutes), appropriate retention time (2.093± 0.01 mi-
nutes for FNF and 1.613± 0.01 minutes for SMV) and the
acceptable tailing or asymmetry factor (Figure 2). Chromato-
graphic parameters such as resolution (Rs), capacity factor (k),
peak symmetry, selectivity (a), and number of theoretical
plates (N) were calculated for the obtained resolution showing
satisfactory separation of the drugs (Table 1). The resolution of
both compounds was studied using this mixture of meth-
anol:water on UHPLC C18 column and system.
3.2. Proposed mechanism of separation
In principle, any separation on reverse-phase column is based
on partition of analytes between the polar mobile phase
and nonpolar stationary phase. Nonpolar (hydrophobic/f simvastatin (SMV) and fenofibrate (FNF). Retention times
rmo Hypersil GOLD 50 mm£ 2.1 mm reversed phase C18
water (80:20, v/v); flow rate 0.4 mL/min; diode array
temperature (22± 1C). The concentration of SMV and FNF
eparation of antihyperlipidemic drugs by green ultrahigh-perfor-
ng the health of liquid chromatography, Journal of Food and Drug
Table 1 e Chromatographic parameters for the separation of simvastatin (SMV) and fenofibrate (FNF).
Drug Resolution (Rs) Peak symmetry Selectivity (a) Capacity factor (k) No. of theoretical plates (N)
SMV 2.32 0.9 1.4 3.0 4265
FNF 1.1 4.2 5285
j o u rn a l o f f o o d and d r u g a n a l y s i s x x x ( 2 0 1 6 ) 1e8 5nonspecific) interactions of SMV and FNF with hydrophobic
(or lipophilic) stationary phase C18 results in different sorption
affinities between the drugs, which promoted their separa-
tion. As SMV (topological polar surface area 72.8 A2) is more
polar than FNF (topological polar surface area 52.6 A2), it
shows more affinity towards the polar mobile as compared to
its affinity towards nonpolar stationary phase, as a result of
which it is less retained as compared to FNF.3.3. Validation of the method
3.3.1. Linearity
The linearity of detector response to different concentrations
of drugs was studied in the range of 0.05e100 mg/mL at eight
different concentrations (0.05 mg/mL, 0.1 mg/mL, 0.5 mg/mL,
1 mg/mL, 5 mg/mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/
mL). The samples were analyzed in triplicates at all concen-
trations. Calibration curves were constructed and found that
correlation coefficient values of both the studied drugs were
observed to be 0.997 for SMV and 0.998 for FNF respectively.Table 2 e Linear regression data for calibration plots for
simvastatin (SMV) and fenofibrate (FNF; n¼ 3).
Parameters FNF SMV
Linearity range
(ng per spot)
0.05e100 mg/mL 0.05e100 mg/mL
Regression equation y¼ 0.525xþ 0.252 y¼ 0.688xþ 0.805
Correlation coefficient 0.99 0.99
Slope ± SD 0.52± 0.02 0.68± 0.01
Confidence interval
of slope
0.52e0.52 0.69e0.68
Intercept± SD 0.25± 0.01 0.80± 0.01
Slope without
intercept± SD
0.52 0.70
Standard error
of slope
0.30 0.39
Standard error
of intercept
0.01 0.02
Confidence interval
of intercept
0.25e0.24 0.80e0.80
SD¼ standard deviation.
Table 3 e Intraday precision of the method (n¼ 3).
Concentration
(mg/mL) FNF
Repeatability (intraday precision) FN
Mean area± SD (mAU*min) RSD (%) Sta
05 2.94± 0.03 1.36
10 5.16± 0.14 2.76
25 14.94± 0.10 0.72
50 28.91± 0.07 0.24
100 54.04± 0.24 0.45
FNF¼ fenofibrate; RSD¼ relative standard deviation; SD¼ standard devia
Please cite this article in press as: Alghazi M, et al., Simultaneous s
mance liquid chromatographyediode array detector method: Improvi
Analysis (2016), http://dx.doi.org/10.1016/j.jfda.2016.03.008The regression analysis data for calibration curves were
calculated using the peak areas and the data are shown in
Table 2.
3.3.2. Precision
The intraday precision (repeatability) of samplewas evaluated
as intraday variation whereas the intermediate precision was
evaluated by measuring inter-day variation for simultaneous
analysis of SMV and FNF at five different concentrations (5 mg/
mL, 10 mg/mL, 25 mg/mL, 50 mg/mL, and 100 mg/mL), in tripli-
cate. Data obtained from determination of repeatability and
intermediate precision expressed as %RSD are shown in
Tables 3 and 4. The lowmagnitude of %RSD indicates the high
repeatability of the method.
3.3.3. Robustness
The robustness of the developed method was determined by
analyzing the samples after deliberate changes were made in
the method parameters, such as flow rate, detection wave-
length and composition of mobile phase. The low magnitude
of %RSD obtained after introducing deliberate small changes
in mobile phase composition indicates the robustness of the
method. Therewas no significant variation of the slopes of the
calibration plots (Table 5).
3.3.4. Recovery
The method employed for the estimation of SMV and FNF in
pharmaceutical formulation after spiking with 50%, 100%, and
150% additional drug. The recovery was in the range of
98.71e101.7%, which suggests satisfactory accuracy of the
method (Table 6).
3.4. Analysis of SMV and FNF in marketed products
Commercially available tablets of SMV and FNF were crushed
and the powder equivalent to one tablet weight was weighed
and diluted with methanol:water (8:2, v/v; or methanol) and
sonicated for 15 minutes and further dilutions were made
with mobile phase to obtain concentrations within the line-
arity range (5 mg/mL, 25 mg/mL, and 50 mg/mL of SMV and FNF,
respectively). All the samples were filtered through a What-
man (GD/X 25, polypropylene, 0.45 mm) syringe filter, beforeF Repeatability (intraday precision) SMV
ndard error Mean area± SD RSD (%) Standard error
0.02 3.15 ± 0.06 2.09 0.03
0.08 6.16 ± 0.18 2.92 0.10
0.06 15.17 ± 0.07 0.47 0.04
0.04 30.02 ± 0.16 0.56 0.09
0.01 59.31 ± 0.43 0.73 0.25
tion; SMV¼ simvastatin.
eparation of antihyperlipidemic drugs by green ultrahigh-perfor-
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Table 4 e Interday precision of the method (n¼ 3).
Concentration
(mg/mL) SMV
Intermediate (interday precision) FNF Intermediate (interday precision) SMV
Mean area± SD (mAU*min) RSD (%) Standard error Mean area± SD RSD (%) Standard error
5 2.68± 0.08 3.20 0.04 3.64± 0.08 3.20 0.04
10 5.10± 0.09 1.92 0.05 6.70± 0.09 1.92 0.05
25 12.45± 0.37 3.02 0.21 16.62± 0.37 3.02 0.21
50 25.24± 0.21 0.84 0.12 33.64± 0.21 0.84 0.12
100 49.41± 0.14 0.29 0.08 65.16± 0.14 0.29 0.08
FNF¼ fenofibrate; RSD¼ relative standard deviation; SD¼ standard deviation; SMV¼ simvastatin.
Table 5 e Robustness of the method.
Parameters FNF SMV
Mean area± SD (mAU*min) RSD (%) Standard error Mean area± SD RSD (%) Standard error
Mobile phase composition 9:1 2.76 ± 0.05 1.99 0.03 3.60 ± 0.05 1.45 0.03
7:3 2.98 ± 0.03 1.15 0.01 3.64 ± 0.04 1.36 0.02
Mobile phase flow rate 0.5 2.83 ± 0.03 1.25 0.02 3.19 ± 0.04 1.29 0.02
0.3 2.87 ± 0.02 1.02 0.01 3.17 ± 0.02 0.75 0.01
Detection wavelength (nm) 250 2.7 ± 0.03 1.19 0.01 3.71 ± 0.05 1.53 0.03
270 2.9 ± 0.02 0.89 0.01 3.64 ± 0.02 0.55 0.01
FNF¼ fenofibrate; RSD¼ relative standard deviation; SD¼ standard deviation; SMV¼ simvastatin.
Table 6 e Results from recovery studies.
Excess
drug
added (%)
FNF SMV
Total
theoretical
content
%Drug recovered SD Standard
error
% Drug recovered SD Standard
error
0 5.00 100.52 0.01 0.01 100.05 0.01 0.01
50 7.50 98.97 0.02 0.04 101.70 0.01 0.01
100 10.00 99.77 0.02 0.01 98.71 0.02 0.01
150 12.50 99.53 0.01 0.01 100.89 0.01 0.01
FNF¼ fenofibrate; SD¼ standard deviation; SMV¼ simvastatin.
j o u r n a l o f f o o d and d r u g an a l y s i s x x x ( 2 0 1 6 ) 1e86placing the samples into the autosampler of UHPLC instru-
ment. The data are shown in Table 6. All obtained values
were within the range of ICH guidelines (98e102%). High
assay value and low RSD (%) of both the drugs in over-the-
counter drugs suggest that the method is suitable for
routine analysis of FNF and SMV of over-the-counter
commercially available drugs. The chromatogram of extrac-
ted FNF and SMV from the marketed tablets was similar to
that of pure drugs indicating the peak purity in all formula-
tions. There was no significant interaction between the drugs
and various excipients present in the pharmaceutical for-
mulations (Table 7).Table 7 e Analysis of simvastatin (SMV) and fenofibrate
(FNF) in marketed products
Amount of
drug in
powder
FNF SMV
% Recovery± SD RSD % Recovery ± SD RSD
5 99.93± 0.07 2.57 99.98± 0.06 2.30
25 99.90± 0.14 1.02 99.92± 0.15 0.96
50 100.03± 0.07 0.25 100.02± 0.08 0.29
SD¼ standard deviation.
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FNF and SMV in developed SEDDS
The developed reversed phase-UHPLC method was found to
be quick, sensitive enough, and suitable for the quantitative
estimation of SMV and FNF. Therefore, this method was put
to test for the estimation of SMV and FNF in the developed
SEDDS. The amount of SMV and FNF in the SEDDS was found
to be 100.45% and 100.17%, respectively. This high assay
value and low %RSD (1.15% for SMV and 0.29% for FNF,
respectively) of both drugs in developed SEDDS indicate that
the method is suitable for simultaneous analysis of devel-
oped SEDDS in bulk drug and marketed products. The chro-
matogram of simultaneous analysis extracted from all the
SEDDS formulations was matching with that of standard
SMV and FNF, showing the purity of peak in tested formu-
lations (Figure 3).4. Conclusion
It can be concluded from the present study that meth-
anolewater mixture can be employed as an environmentallyeparation of antihyperlipidemic drugs by green ultrahigh-perfor-
ng the health of liquid chromatography, Journal of Food and Drug
Figure 3 e Application of the developed green chromatographic method for the detection of simvastatin (SMV) and
fenofibrate (FNF) in self-emulsifying drug delivery systems.
j o u rn a l o f f o o d and d r u g a n a l y s i s x x x ( 2 0 1 6 ) 1e8 7benign eluent for the simultaneous analysis of anti-
hyperlipidemic drugs. Hydrophobic (nonpolar) interactions of
the drugs with hydrophobic (or lipophilic) stationary phase
C18 were the forces responsible for their separation. The
developed method was found to be linear over a wide con-
centration range as well as exhibiting good precision,
robustness, and recovery properties. The newly developed
method was found applicable for the simultaneous separa-
tion of SMV and FNF in marketed formulations and SEDDS,
indicating its suitability for the routine analysis of these
drugs. Another important conclusion of this study was that
these green eluents have the potential to be used for analysis
in chromatographic science and thus making the separation
process more environment friendly. Safer alternatives should
be explored on the basis of their environmental, health, and
safety and life-cycle assessment to replace traditional sol-
vents making separation science green because developing
green analytical methods to come in place of traditional ones
is a crucial requirement.Conflicts of interest
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